Literature DB >> 9198184

Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis.

M Nesheim1, W Wang, M Boffa, M Nagashima, J Morser, L Bajzar.   

Abstract

The thrombin thrombomodulin dependent activation of the plasma protein TAFI (Thrombin Activatable Fibrinolysis Inhibitor) and Subsequent Inhibition of Fibrinolysis by the TAFIa is described. Work to date indicates that TAFIa is a carboxypeptidase B enzyme that suppress fibrinolysis most likely by down regulating the cofactor functions of partially degraded fibrin. The existence of TAFI provides the explanation for the apparent profibrinolytic effect of activated protein C. and implies the existence of an explicit molecular connection between the blood coagulation of fibrinolytic cascades that is expressed through the thrombin thrombomodulin dependent activation of TAFI. Thus, thrombin generation can, in principle, result in the suppression of fibrinolysis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9198184

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  26 in total

Review 1.  Molecular basis of thrombolytic therapy.

Authors:  H R Lijnen; D Collen
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

Review 2.  The use of recombinant activated coagulation factor VII for spine surgery.

Authors:  Richard B Weiskopf
Journal:  Eur Spine J       Date:  2004-05-25       Impact factor: 3.134

3.  Differential exoprotease activities confer tumor-specific serum peptidome patterns.

Authors:  Josep Villanueva; David R Shaffer; John Philip; Carlos A Chaparro; Hediye Erdjument-Bromage; Adam B Olshen; Martin Fleisher; Hans Lilja; Edi Brogi; Jeff Boyd; Marta Sanchez-Carbayo; Eric C Holland; Carlos Cordon-Cardo; Howard I Scher; Paul Tempst
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

4.  Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N.

Authors:  Mercy O Quagraine; Fulong Tan; Hironori Tamei; Ervin G Erdös; Randal A Skidgel
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

5.  Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.

Authors:  Laurent O Mosnier
Journal:  J Biol Chem       Date:  2010-11-01       Impact factor: 5.157

6.  Polyphosphate modulates blood coagulation and fibrinolysis.

Authors:  Stephanie A Smith; Nicola J Mutch; Deepak Baskar; Peter Rohloff; Roberto Docampo; James H Morrissey
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-12       Impact factor: 11.205

Review 7.  Chemodiversity in freshwater and terrestrial cyanobacteria - a source for drug discovery.

Authors:  George E Chlipala; Shunyan Mo; Jimmy Orjala
Journal:  Curr Drug Targets       Date:  2011-10       Impact factor: 3.465

8.  Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.

Authors:  Yuko Suzuki; Hideto Sano; Liina Mochizuki; Naoki Honkura; Tetsumei Urano
Journal:  Blood Adv       Date:  2020-11-10

9.  Does the oxidation of methionine in thrombomodulin contribute to the hypercoaguable state of smokers and diabetics?

Authors:  Wesley E Stites; Jeffrey W Froude
Journal:  Med Hypotheses       Date:  2006-10-24       Impact factor: 1.538

10.  Guidance on patient identification and administration of recombinant human activated protein C for the treatment of severe sepsis.

Authors:  Gary Garber; Rt Noel Gibney; Bruce Light; Claudio Martin; Kenneth Cunningham; Jean-Gilles Guimond; Sheldon Magder; James Russell
Journal:  Can J Infect Dis       Date:  2002-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.